Loading
A phase 2 trial of Intismeran autogene, Pembrolizumab in melanoma, run by ModernaTX, Inc., active and no longer recruiting.
An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942) is a phase 2 interventional study registered as NCT03897881 by ModernaTX, Inc., with 267 participants enrolled, started 2019-07-18 and due to reach its primary completion in 2032-11-21. Interventions recorded: mRNA-4157, Pembrolizumab. Conditions listed: Melanoma. No results are recorded here; the registry entry is the source.
A second publication from the trial, later than the first and described in its title as an update or longer-term analysis. Read it with the primary publication linked from the trial page; the record was linked automatically and its figures have not been checked by hand.
For the first time a randomised trial suggests that a vaccine tailored to an individual's tumour can reduce relapse when combined with immunotherapy, which is a proof of concept for a field that had failed for decades. Nothing changes for patients yet: the trial was small, the confidence interval crossed one, and the phase 3 trial in melanoma (and parallel trials in lung and other cancers) must confirm it. If it does, personalised mRNA vaccines could become a routine adjunct to checkpoint inhibitors after surgery.
Shares KEYNOTE-942: a personalised mRNA cancer vaccine plus pembrolizumab after melanoma surgery, Moderna, Intismeran autogene, Stage III melanoma (after surgery).
Shares KEYNOTE-942: a personalised mRNA cancer vaccine plus pembrolizumab after melanoma surgery, Intismeran autogene, Stage III melanoma (after surgery), Melanoma.
Shares Intismeran autogene, Melanoma, Pembrolizumab, Immune checkpoint inhibitors.
Shares KEYNOTE-942: a personalised mRNA cancer vaccine plus pembrolizumab after melanoma surgery, Melanoma, Immune checkpoint inhibitors.
Shares Intismeran autogene, Pembrolizumab, Immune checkpoint inhibitors.
Shares Intismeran autogene, Melanoma, Pembrolizumab, Immune checkpoint inhibitors.
Shares Stage III melanoma (after surgery), Melanoma, Pembrolizumab, Immune checkpoint inhibitors.
Shares Stage III melanoma (after surgery), Melanoma, Pembrolizumab, Immune checkpoint inhibitors.